By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Current study results on Immunization have been published. According to news reporting originating from Taipei, Taiwan, by NewsRx correspondents, research stated, "Dioscorea tuber phytoextracts can confer immunomodulatory activities ex vivo and improve regeneration of bone marrow cells in vivo. In present study, we evaluated specific Dioscorea phytoextracts for use ex vivo as a bone-marrow-derived dendritic cell-(DC-) based vaccine adjuvant for cancer immunotherapy."
Our news editors obtained a quote from the research from the Institute of Agriculture, "Fractionated Dioscorea extracts (DsII) were assayed for their effect on maturation and functions of DC ex vivo and antimelanoma activity of DC-based vaccine in vivo. The phytoextract from 50-75% ethanol-precipitated fraction of Dioscorea alata var. purpurea Tainung no. 5 tuber, designated as DsII-TN5, showed a strong augmentation of tumor cell lysate- (TCL-) loaded DC-mediated activation of T-cell proliferation. DsII-TN5 stimulated the expression of CD40, CD80, CD86, and IL-1 beta in TCL-loaded DCs and downregulated the expression of TGF-beta 1. DC vaccines prepared by a specific schema (TCL (2 h) + LPS (22 h)) showed the strongest antitumor activity. DsII-TN5 as a DC vaccine adjuvant showed strong antimelanoma activity and reduced myeloid-derived suppressor cell (MDSC) population in tested mice. DsII-TN5 can also activate DCs to enhance Th1- and Th17-related cytokine expressions. Biochemical analysis showed that DsII-TN5 consists mainly of polysaccharides containing a high level (53%) of mannose residues."
According to the news editors, the research concluded: "We suggest that DsII-TN5 may have potential for future application as a potent, cost-effective adjuvant for DC-based cancer vaccines."
For more information on this research see: Specific Dioscorea Phytoextracts Enhance Potency of TCL-Loaded DC-Based Cancer Vaccines. Evidence-Based Complementary and Alternative Medicine, 2013;():1-13. Evidence-Based Complementary and Alternative Medicine can be contacted at: Hindawi Publishing Corporation, 410 Park Avenue, 15TH Floor, #287 Pmb, New York, NY 10022, USA. (Hindawi Publishing - www.hindawi.com; Evidence-Based Complementary and Alternative Medicine - www.hindawi.com/journals/ecam/)
The news editors report that additional information may be obtained by contacting W.T. Chang, Academy Sinica, Inst Agr Biotechnol Res Center, Taipei 11529, Taiwan. Additional authors for this research include H.M. Chen, S.Y. Yin, Y.H. Chen, C.C. Wen, W.C. Wei, P. Lai, C.H. Wang and N.S. Yang (see also Immunization).
Keywords for this news article include: Asia, Taipei, Taiwan, Oncology, Immunization, Immunotherapy, Dendritic Cell, Cancer Vaccines, Immunomodulation, Biological Products
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC